Introduction to the mechanism of action and scope of application of pimotebi

Pimitespib is an oral small molecule HSP90 inhibitor that mainly works by interfering with heat shock protein 90 90, HSP90) function, thereby exerting anti-tumor effects. HSP90 is an important molecular chaperone that is widely present in eukaryotic cells and is responsible for the folding, stability and functional maintenance of many key proteins. Many signaling pathway proteins closely related to tumor occurrence and development (such as EGFR, HER2, AKT, BRAF, etc.) are all "client proteins" of HSP90. Pimetibib inhibits the growth and survival of cancer cells by blocking the ATP enzyme activity of HSP90, preventing these key proteins from folding correctly or being degraded.

As a new type of HSP90 inhibitor, pimetibi has significantly improved selectivity, safety and oral usability compared with earlier HSP90 inhibitors. It is specifically designed to be administered orally and has strong tumor tissue enrichment capabilities, helping to improve anti-tumor effects and reduce toxicity to normal tissues. In addition, pimetibib has an inhibitory effect on both the α and β isoforms of HSP90 and can cover HSP90-dependent signaling pathways in a variety of malignant tumors.

In terms of indications, pimetibi is currently mainly used to treat gastrointestinal stromal tumors (GIST), especially patients who are resistant to first- and second-line targeted therapies such as imatinib, sunitinib and regorafenib. In 2022, Japan’s Ministry of Health, Labor and Welfare officially approved pimotebi for the treatment of patients with advanced or metastatic GIST who have failed previous standard treatments. This provides a new treatment option for these patients. Studies have shown that pimetibi has a certain effect on prolonging progression-free survival in multi-line treatment of GIST with controllable toxicity. It is currently one of the important options for the fourth-line treatment of GIST.

EXCEPTGIST, The research of pimetibi in other solid tumors is also continuing to advance, including lung cancer, breast cancer, prostate cancer, etc. Since the kinesins of many cancers depend on the stability of HSP90, pimotebib theoretically has potential value in these areas as well. In the future, pimetibib may play a greater role in strategies combining immunotherapy or other targeted drugs, especially in patients with advanced solid tumors with complex drug resistance mechanisms and limited treatment options. HSP90 inhibitors are one of the breakthrough treatment pathways. With the deepening of research, the clinical application scope of pimoteb is expected to be further expanded.

Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/

xa0